Logo

Invitae: Michael Korn

Mar 16, 2023

Invitae appointed Michael Korn as its chief medical officer for oncology, effective March 13. Korn previously served as CMO at Caris Life Sciences and remains on the faculty at the University of California, San Francisco as a volunteer clinical professor in the division of hematology/oncology. At UCSF, he founded and led the Precision Oncology Initiative and the molecular tumor board and was the lead investigator of clinical trials exploring new treatments for advanced cancers. He obtained his medical degree from the Philipps University Marburg and graduated from the University of Düsseldorf in Germany. He completed his internal medicine and medical oncology training at the West German Cancer Center - University Hospital Essen.

Breaking News
The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.